

### **Tocilizumab** Infusion Therapy Plan Orders

#### Page 1 of 2

Name: \_\_\_

Kaiser Permanente Member I.D. #\_\_\_\_\_

Date of Birth \_\_\_\_

form to the influsion center where the patient will be receiving treatment (see fax numbers at the end of this protocol). Lab orders are not included on this form – place orders via usual method. Lab monitoring is the responsibility of the ordering physician. Please complete all of the following: Pre-Service Authorization has been obtained by Kaiser Permanente Fax: 1-888-282-2685 Voice: 1-800-289-1363 Order Date:	Instructions to Provider Review orders and note any changes. All orders	with ☑ will be placed unless otherwise noted. Please fax completed order		
Prease complete all of the following:         □ Pre-Service Authorization has been obtained by Kaiser Permanente Fax: 1-888-282-2685 Voice: 1-800-289-1363         Order Date:       ICD-10 code (REQUIRED):         Weight:       kg         ICD-10 description       ICD-10 description         General Plan Communication       Elosimiliar tocilizumab-aazg (Tyenne) is the preferred and defaulted agent in this plan         • Special instructions/notes:	Lab orders are not included on this form - place of			
Order Date:				
Order Date:       ICD-10 code ( <i>REQUIRED</i> ):         Weight:      kg         ICD-10 description         General Plan Communication         • Biosimilar tocilizumab-aazg (Tyenne) is the preferred and defaulted agent in this plan         • Special instructions/notes:         Provider Information         • Screen for viral hepatitis prior to use; anti-rheumatic therapy may cause reactivation of hepatitis B         • Ensure baseline PPD or quantiFERON-TB assay for latent TB         • Live vaccines should not be given concurrently or within 3 months of discontinuation of therapy         • Do not combine with tumor necrosis factor (TNF) agents or other biologic DMARDs         • Patient requires monitoring of CBC w/diff and AST/ALT every 4 weeks prior to each treatment         • Review lipid panel 4 and 8 weeks after initiation, then every 6 months         Infusion Therapy         ✓ tocilizumab-aazg (TYENNE) in 0.9% sodium chloride 100 mL IV infusion         Dose: ✓ 4 mg/kg x weight (kg) = Total Dose       mg <i>Route:</i> Intravenous       mg <i>Route:</i> Intravenous       mg <i>Brequency:</i> Once every 4 weeks <i>Infusion-related reaction:</i> 1) STOP infusion immediately: 2) Increase primary infusion to wide open rate; 3) Administer PRN         medications per hypersensitivity protocol; 4) Notify MD       Note any changes to above regimen:         Pre-Meds	Pre-Service Authorization has been obtain	ned by Kaiser Permanente <b>Fax:</b> 1-888-282-2685 <b>Voice</b> : 1-800-289-1363		
Weight:      kg       ICD-10 code ( <i>REQURED</i> ):         General Plan Communication       . <ul> <li>Biosimilar tocilizumab-aazg (Tyenne) is the preferred and defaulted agent in this plan</li> <li>Special instructions/notes:</li> <li></li></ul>	Order Date:	Diagnosis:		
General Plan Communication         • Biosimilar tocilizumab-aazg (Tyenne) is the preferred and defaulted agent in this plan         • Special instructions/notes:         Provider Information         • Screen for viral hepatitis prior to use; anti-rheumatic therapy may cause reactivation of hepatitis B         • Ensure baseline PPD or quantERRON-TB assay for latent TB         • Live vaccines should not be given concurrently or within 3 months of discontinuation of therapy         • Do not combine with tumor necrosis factor (TNF) agents or other biologic DMARDs         • Patient requires monitoring of CBC w/dff and AST/ALT every 4 weeks prior to each treatment         • Review lipid panel 4 and 8 weeks after initiation, then every 6 months         Infusion Therapy         ✓ tocilizumab-aazg (TYENNE) in 0.9% sodium chloride 100 mL IV infusion         Dose: ☑ 4 mg/kg x weight (kg) = Total Dosemg		ICD-10 code (REQUIRED):		
<ul> <li>Biosimilar tocilizumab-aazg (Tyenne) is the preferred and defaulted agent in this plan</li> <li>Special instructions/notes:</li></ul>	Weight:kg	ICD-10 description		
<ul> <li>Special instructions/notes:</li></ul>	General Plan Communication			
<ul> <li>Screen for viral hepatitis prior to use; anti-rheumatic therapy may cause reactivation of hepatitis B</li> <li>Ensure baseline PPD or quanifFERON-TB assay for latent TB</li> <li>Live vaccines should not be given concurrently or within 3 months of discontinuation of therapy</li> <li>Do not combine with tumor necrosis factor (TNF) agents or other biologic DMARDs</li> <li>Patient requires monitoring of CBC widiff and AST/ALT every 4 weeks prior to each treatment</li> <li>Review lipid panel 4 and 8 weeks after initiation, then every 6 months</li> <li>Infusion Therapy</li> <li>✓ tocilizumab-aazg (TYENNE) in 0.9% sodium chloride 100 mL IV infusion</li> <li>Dose: ☑ 4 mg/kg x weight (kg) = Total Dose mg</li> <li>Route: Intravenous</li> <li>Frequency: Once every 4 weeks</li> <li>If infusion-related reaction:</li> <li>1) STOP infusion immediately; 2) Increase primary infusion to wide open rate; 3) Administer PRN medications per hypersensitivity protocol; 4) Notify MD</li> <li>Note any changes to above regimen:</li></ul>				
<ul> <li>Ensure baseline PPD or quantiFERON-TB assay for latent TB</li> <li>Live vaccines should not be given concurrently or within 3 months of discontinuation of therapy</li> <li>Do not combine with tumor necrosis factor (TNF) agents or other biologic DMARDs</li> <li>Patient requires monitoring of CBC w/diff and AST/ALT every 4 weeks prior to each treatment</li> <li>Review lipid panel 4 and 8 weeks after initiation, then every 6 months</li> <li>Infusion Therapy</li> <li>d tocilizumab-aazg (TYENNE) in 0.9% sodium chloride 100 mL IV infusion</li> <li>Dose: 2 4 mg/kg x weight (kg) = Total Dose mg</li> <li>Route: Intravenous</li> <li>Frequency: Once every 4 weeks</li> <li>Infusion-related reaction:         <ol> <li>STOP infusion immediately; 2) Increase primary infusion to wide open rate; 3) Administer PRN medications per hypersensitivity protocol; 4) Notify MD</li> </ol> </li> <li>Note any changes to above regimen:</li></ul>	Provider Information			
<ul> <li>Do not combine with tumor necrosis factor (TNF) agents or other biologic DMARDs</li> <li>Patient requires monitoring of CBC w/diff and AST/ALT every 4 weeks prior to each treatment</li> <li>Review lipid panel 4 and 8 weeks after initiation, then every 6 months</li> </ul> Infusion Therapy If tocilizumab-aazg (TYENNE) in 0.9% sodium chloride 100 mL IV infusion Dose: If 4 mg/kg x weight (kg) = Total Dose mg <ul> <li>B mg/kg x weight (kg) = Total Dose mg</li> <li>Route: Intravenous</li> <li>Frequency: Once every 4 weeks</li> <li>Infusion-related reaction:</li> <li>STOP infusion immediately: 2) Increase primary infusion to wide open rate; 3) Administer PRN medications per hypersensitivity protocol; 4) Notify MD Note any changes to above regimen:</li></ul>	Ensure baseline PPD or quantiFERON	<ul> <li>Screen for viral hepatitis prior to use; anti-rheumatic therapy may cause reactivation of hepatitis B</li> <li>Ensure baseline PPD or quantiFERON-TB assay for latent TB</li> </ul>		
<ul> <li>Review lipid panel 4 and 8 weeks after initiation, then every 6 months</li> <li>Infusion Therapy         <ul> <li>Infusion Therapy</li> <li>Inf</li></ul></li></ul>				
<ul> <li>✓ tocilizumab-aazg (TYENNE) in 0.9% sodium chloride 100 mL IV infusion <i>Dose</i>: ☑ 4 mg/kg x weight (kg) = Total Dosemg</li></ul>		<ul> <li>Patient requires monitoring of CBC w/diff and AST/ALT every 4 weeks prior to each treatment</li> </ul>		
Dose: ☑ 4 mg/kg x weight (kg) = Total Dose mg         □ 8 mg/kg x weight (kg) = Total Dose mg         Route: Intravenous         Frequency: Once every 4 weeks         Infusion-related reaction:         1) STOP infusion immediately; 2) Increase primary infusion to wide open rate; 3) Administer PRN medications per hypersensitivity protocol; 4) Notify MD         Note any changes to above regimen:	Infusion Therapy			
Pre-Meds         □ acetaminophen (TYLENOL) tablet         Dose: 650 mg       Route: Oral       Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion         May also be given once as needed during infusion for achiness, headache, or fever if not given prior to infusion       □         cetirizine (ZYRTEC) tablet       Dose: 10 mg       Route: Oral       Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion         Frequency: Once, at least 30 minutes prior to tocilizumab-aazg infusion (if not taken at home)       □       hydrocortisone sodium succinate (SOLU-CORTEF) injectable [not routine; only if breakthrough reaction]       Dose: 50 mg       Route: Oral       Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion in addition to acetaminophen and antihistamine if patient still experiences symptoms with acetaminophen and antihistamine alone         Other:	Dose: ☑ 4 mg/kg x weight (kg) = □ 8 mg/kg x weight (kg) = Route: Intravenous Frequency: Once every 4 weeks Infuse over: 60 minutes If infusion-related reaction: 1) STOP infusion immediately; 2	Total Dose mg         Total Dose mg         P) Increase primary infusion to wide open rate; 3) Administer PRN		
<ul> <li>□ acetaminophen (TYLENOL) tablet</li> <li>Dose: 650 mg Route: Oral Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion</li> <li>May also be given once as needed during infusion for achiness, headache, or fever if not given prior to infusion</li> <li>□ cetirizine (ZYRTEC) tablet</li> <li>Dose: 10 mg Route: Oral Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion</li> <li>Frequency: Once, at least 30 minutes prior to tocilizumab-aazg infusion (if not taken at home)</li> <li>□ hydrocortisone sodium succinate (SOLU-CORTEF) injectable [not routine; only if breakthrough reaction]</li> <li>Dose: 50 mg Route: Oral Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion in addition to acetaminophen and antihistamine if patient still experiences symptoms with acetaminophen and antihistamine alone</li> <li>□ Other:</li></ul>	Note any changes to above regimen:			
Dose: 650 mg       Route: Oral       Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion         May also be given once as needed during infusion for achiness, headache, or fever if not given prior to infusion         cetirizine (ZYRTEC) tablet         Dose: 10 mg       Route: Oral       Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion         Frequency: Once, at least 30 minutes prior to tocilizumab-aazg infusion (if not taken at home)         hydrocortisone sodium succinate (SOLU-CORTEF) injectable [not routine; only if breakthrough reaction]         Dose: 50 mg       Route: Oral       Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion in addition to acetaminophen and antihistamine if patient still experiences symptoms with acetaminophen and antihistamine alone         Other:	Pre-Meds			
<ul> <li>cetirizine (ZYRTEC) tablet         <ul> <li>Dose: 10 mg</li> <li>Route: Oral</li> <li>Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion</li> <li>Frequency: Once, at least 30 minutes prior to tocilizumab-aazg infusion (if not taken at home)</li> </ul> </li> <li>hydrocortisone sodium succinate (SOLU-CORTEF) injectable [not routine; only if breakthrough reaction]</li> <li>Dose: 50 mg</li> <li>Route: Oral</li> <li>Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion in addition to acetaminophen and antihistamine if patient still experiences symptoms with acetaminophen and antihistamine alone</li> </ul> <li>Other:         <ul> <li>Dose: Route: Oral</li> <li>Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion</li> </ul> </li> <li>No routine pre-medications necessary. Above medications may be given if patient has reaction and requires pre-medications for future doses</li>	Dose: 650 mg Route: Oral Free May also be given once as needed			
<ul> <li>Dose: 50 mg Route: Oral Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion in addition to acetaminophen and antihistamine if patient still experiences symptoms with acetaminophen and antihistamine alone</li> <li>Other: Route: Oral Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion</li> <li>✓ No routine pre-medications necessary. Above medications may be given if patient has reaction and requires pre-medications for future doses</li> </ul>	cetirizine (ZYRTEC) tablet Dose: 10 mg Route: Oral Free			
Dose: Route: Oral Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion ✓ No routine pre-medications necessary. Above medications may be given if patient has reaction and requires pre-medications for future doses	Dose: 50 mg Route: Oral Free acetaminophen and antihistamine i antihistamine alone	quency: Once, 30 minutes prior to tocilizumab-aazg infusion in addition to		
·	Dose: Route: Oral Fre ☑ No routine pre-medications necessary	Dose: Route: Oral Frequency: Once, 30 minutes prior to tocilizumab-aazg infusion No routine pre-medications necessary. Above medications may be given if patient has reaction and requires		
	· · ·	Date:		

HIM

Revision Date: 5/28/2024 Kaiser Permanente <Reference#115105>

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

# KAISER PERMANENTE®

# Tocilizumab

Infusion Therapy Plan Orders

#### Page 2 of 2

Name: \_\_\_\_

Kaiser Permanente Member I.D. # \_\_\_\_\_

Date of Birth \_\_\_\_\_

V Line	Caro	
	0.9% sodium chloride infusion 250 mL	
V		ncy: Run continuously to keep vein open
nfusio	n Reaction Meds	
	albuterol (PROVENTIL) nebulizer solution 0.0839	/~
	Dose: 2.5 mg Route: Nebulization Freque	ency: PRN for shortness of breath/wheezing
	diphenhydrAMINE (BENADRYL) injectable <i>Dose:</i> 25 mg <i>Route:</i> Intravenous <i>Frequen</i> shortness of breath. May repeat in 15 minute	<i>ncy:</i> Once PRN, May repeat x1 for urticaria, pruritus, es if symptoms not resolved
	view for Nursing	
Conti •	inue with infusion only if patient meets the followin ANC greater than or equal to 2,000 (first dose) o Platelets greater than or equal to 100,000	g criteria: or greater than or equal to 1,000 (subsequent doses)
•	AST/ALT less than 1.5 x ULN	
•	Verify lipid panel drawn at 4 and 8 weeks after in	
•	If lipid panel labs not drawn prior to treatment, in proceed with infusion	struct patient to have labs drawn and notify provider, but
lursing	g Orders	
•	infuse tocilizumab-aazg without negative TB res Do not administer tocilizumab-aazg and notify pr	rovider if patient has a temperature greater than 100° F, Il illness, or if patient is taking antibiotics for current infection
Referer	nces	
•	TYENNE® (tocilizumab-aazg) Injection, for intra	venous infusion prescribing information.
Kaiser	Permanente Infusion Locations	
Ca Ev Oly	ellevue Medical Center         11511 NE 10 <sup>th</sup> St, Bellevue, WA 98004         Fax: 425-502-3512       Phone: 425-502-3510         pitol Hill Medical Center         201 16 <sup>th</sup> Ave E, Seattle WA 98112         Fax: 206-326-2104       Phone: 206-326-3109         verett Medical Center         2930 Maple St, Everett, WA 98201         Fax: 425-261-1578       Phone: 425-261-1566         ympia Medical Center         700 Lilly Road N.E., Olympia, WA 98506         Fax: 360-923-7106       Phone: 360-923-7164	Riverfront Medical Center – Spokane W 322 North River Drive, Spokane, WA 99201 Fax: 509-324-7168 Phone: 509-241-2073 Silverdale Medical Center 10452 Silverdale Way NW, Silverdale, WA 98383 Fax: 360-307-7421 Phone: 360-307-7316 Tacoma Medical Center 209 Martin Luther King Jr Way, Tacoma, WA 98405 Fax: 253-383-6262 Phone: 253-596-3666

Provider Signature: \_\_\_\_\_

Printed Name: \_\_\_\_\_

\_\_\_\_\_ Date: \_\_\_\_\_

НІМ